Drug Deal Disclosure Act
- Bill Number
- S. 4355
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-04-21: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-05-14T16:37:18Z
AI-Generated Summary
Drug Deal Disclosure Act (S. 4355)
Purpose
To mandate the Department of Health and Human Services (HHS) to publicly release documents, communications, and other records related to certain confidential drug pricing agreements between federal entities and drug manufacturers, promoting transparency in deals involving most-favored-nation (MFN) pricing and similar arrangements.
Key Provisions
- Public Disclosure Requirement (Sec. 2):
- HHS Secretary must release, within 30 days of enactment, all relevant records (e.g., documents, emails, contracts, notes) in a searchable, downloadable format.
- Covers agreements entered on or after January 20, 2025, between the Executive Office of the President, HHS, Department of Commerce, or other federal entities and drug manufacturers.
- Targeted agreement types include:
- Reduced U.S. drug prices referencing foreign prices (e.g., for Medicare/Medicaid).
- Direct-to-consumer sales/discounts (e.g., via manufacturer websites or "TrumpRx").
- Import duty exemptions.
- U.S. investments or revenue repatriation.
- Special treatment in Medicare/Medicaid innovation models (e.g., "GLOBE" or "GUARD").
- Contributions to the Strategic National Stockpile.
- FDA priority review vouchers.
- Lists 16 specific agreements with companies like AbbVie, Pfizer, and Merck (announced Oct 2025–Jan 2026).
- Future or amended agreements must also be disclosed within 30 days.
- Withholding Rules (Sec. 2(b)-(c)):
- Prohibited: Withholding for reputational or political reasons.
- Permitted: Redactions for proprietary pricing data, foreign legal prohibitions, or other laws; requires disclosure of access to info, written justification published in the Federal Register, and submission to Congress.
- Congressional Report (Sec. 3): Within 15 days of releasing listed agreements, HHS reports to key Senate/House committees on released/withheld items and redaction summaries.
- CBO/GAO Analysis (Sec. 4): Joint report within 90 days analyzing economic/budgetary effects, including:
- Cost savings for individuals (by insurance status, including uninsured).
- Impacts on Medicare, Medicaid, and ACA exchanges.
- Effects on drug competition, anti-kickback laws, and health plan designs.
Significant Changes to Existing Law
- Introduces a strict disclosure mandate for executive-branch drug pricing deals, overriding typical confidentiality in negotiations.
- Limits redactions compared to standard Freedom of Information Act (FOIA) exemptions by banning political/reputational withholdings and requiring public justifications.
Potential Impacts
- Government Agencies: HHS faces tight deadlines for data compilation/release; increased oversight via reports to Congress and CBO/GAO analyses.
- Citizens/Patients: Greater transparency on drug pricing deals could inform public debate on costs/savings in Medicare/Medicaid; potential insights into consumer discounts.
- Drug Manufacturers: Exposure of deal details may affect negotiations and competitiveness.
- International Relations: Indirect, via scrutiny of foreign-price referencing, but no direct changes to trade/diplomacy.
Main Stakeholders Affected
- Federal Agencies: HHS (lead), Executive Office, Commerce, FDA, CMS (Medicare/Medicaid).
- Drug Manufacturers: 16 named companies (e.g., Pfizer, Eli Lilly) and future participants.
- Congress: Receives reports; committees oversee health/finance.
- Public/Analysts: Patients, researchers via public data; CBO/GAO for fiscal reviews.
- Health Programs: Medicare/Medicaid beneficiaries, ACA plans.
Notable Legal, Constitutional, or Political Implications
- Legal: Balances transparency with proprietary protections; enforceable via congressional reporting but lacks explicit penalties for non-compliance.
- Constitutional: Supports oversight of executive actions without infringing separation of powers.
- Political: Targets post-2025 deals, enabling scrutiny of executive drug pricing strategies; fosters accountability in federal-pharma negotiations.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (18)
Sen. Welch, Peter [D-VT], Sen. Warren, Elizabeth [D-MA], Sen. Gallego, Ruben [D-AZ], Sen. Merkley, Jeff [D-OR], Sen. Luján, Ben Ray [D-NM], Sen. Baldwin, Tammy [D-WI], Sen. Whitehouse, Sheldon [D-RI], Sen. Kelly, Mark [D-AZ], Sen. Sanders, Bernard [I-VT], Sen. Warner, Mark R. [D-VA], Sen. Smith, Tina [D-MN], Sen. Hassan, Margaret Wood [D-NH], Sen. Cortez Masto, Catherine [D-NV], Sen. Bennet, Michael F. [D-CO], Sen. Warnock, Raphael G. [D-GA], Sen. Hirono, Mazie K. [D-HI], Sen. Cantwell, Maria [D-WA], Sen. Van Hollen, Chris [D-MD]
Recent Actions
- 2026-04-21: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2026-04-21: Introduced in Senate
Bill Versions
- Drug Deal Disclosure Act — issued 2026-04-21 — PDF (9 pages)